Psoriasis

Psoriasis, an inflammatory skin disease, is often linked to many comorbidities that affect treatment decisions and the overall management of the disorder, according to new research.

Patients with psoriasis often have lower success treatments with biologic agents in clinical practice than clinical trials, leading to higher doses and therefore higher annual treatment costs.

Pfizer's biosimilar to Remicade is expected to be available in pharmacies by the end of November.

The 4-part lecture, “Practical Application of Novel Targeted Strategies in Moderate-to-Severe Atopic Dermatitis” covered the pathogenesis of atopic dermatitis (AD), new insights into the pathophysiology in AD, considerations for change in the treatment of AD, and the latest developments in treatment.

Over the past several years, an increased understanding of the pathophysiology of psoriasis and psoriatic arthritis has led to the development of several new biologic therapies.

This case study from the National Psoriasis Foundation describes its aim to eliminate access barriers-including cost-through legislative and regulatory advocacy, direct patient assistance programs, and engagement with health insurers.

A few weeks ago, Novo Nordisk ($NVO) said it had lost Express Scripts' business on two of its top drugs, Victoza and NovoLog. Well, that was just part of the action at the pharmacy benefits manager.